HLA-A and neoplasm: HLA-A*02:01 has been shown to restrict HLA-A-specific recognition of various tumor peptides by T lymphocytes [35] thus showing a prominent role in the design of therapeutic cancer vaccines and also chimeric antigen receptor T cell-based immunotherapies [36].